Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
21
06
2021
accepted:
06
04
2022
revised:
12
03
2022
pubmed:
23
4
2022
medline:
21
5
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
Psychedelic-assisted psychotherapy gained considerable interest as a novel treatment strategy for fear-related mental disorders but the underlying mechanism remains poorly understood. The serotonin 2A (5-HT2A) receptor is a key target underlying the effects of psychedelics on emotional arousal but its role in fear processing remains controversial. Using the psychedelic 5-HT2A/5-HT2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) and 5-HT2A receptor knockout (KO) mice we investigated the effect of 5-HT2A receptor activation on emotional processing. We show that DOI administration did not impair performance in a spontaneous alternation task but reduced anxiety-like avoidance behavior in the elevated plus maze and elevated zero maze tasks. Moreover, we found that DOI did not block memory recall but diminished fear expression in a passive avoidance task. Likewise, DOI administration reduced fear expression in an auditory fear conditioning paradigm, while it did not affect retention of fear extinction when administered prior to extinction learning. The effect of DOI on fear expression was abolished in 5-HT2A receptor KO mice. Administration of DOI induced a significant increase of c-Fos expression in specific amygdalar nuclei. Moreover, local infusion of the 5-HT2A receptor antagonist M100907 into the amygdala reversed the effect of systemic administration of DOI on fear expression while local administration of DOI into the amygdala was sufficient to suppress fear expression. Our data demonstrate that activation of 5-HT2A receptors in the amygdala suppresses fear expression but provide no evidence for an effect on retention of fear extinction.
Identifiants
pubmed: 35449450
doi: 10.1038/s41386-022-01324-2
pii: 10.1038/s41386-022-01324-2
pmc: PMC9117291
doi:
Substances chimiques
Amphetamines
0
Hallucinogens
0
Receptor, Serotonin, 5-HT2A
0
Receptor, Serotonin, 5-HT2C
0
Serotonin 5-HT2 Receptor Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1304-1314Informations de copyright
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Battle DE. Diagnostic and statistical manual of mental disorders (DSM). Codas. 2013;25:191–2.
pubmed: 24413388
doi: 10.1590/S2317-17822013000200017
Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376:2459–69.
pubmed: 28636846
doi: 10.1056/NEJMra1612499
Maria M, Steenkamp P. Psychotherapy for military-Related PTSD: a review of randomized clinical trials. JAMA. 2015;314:489–500.
doi: 10.1001/jama.2015.8370
Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33:792–806.
pubmed: 27126398
doi: 10.1002/da.22511
Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br J Psychiatry. 2015;206:93–100.
pubmed: 25644881
doi: 10.1192/bjp.bp.114.148551
Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214–27.
pubmed: 15677582
doi: 10.1176/appi.ajp.162.2.214
Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48:1975–84.
pubmed: 29254516
doi: 10.1017/S003329171700349X
Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol. 2012;63:129.
pubmed: 22129456
pmcid: 4942586
doi: 10.1146/annurev.psych.121208.131631
Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharm Ther. 2015;149:150–90.
doi: 10.1016/j.pharmthera.2014.12.004
Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharm Ther. 2019;204:107402.
doi: 10.1016/j.pharmthera.2019.107402
Sessa B. Turn on and tune in to evidence-based psychedelic research. Lancet Psychiatry. 2015;2:10–2.
pubmed: 26359597
doi: 10.1016/S2215-0366(14)00120-5
Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet. Psychiatry. 2016;3:481–8.
pubmed: 27067625
Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic drugs in biomedicine. Trends Pharm Sci. 2017;38:992–1005.
pubmed: 28947075
doi: 10.1016/j.tips.2017.08.003
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177:391–410.
pubmed: 32098487
doi: 10.1176/appi.ajp.2019.19010035
Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385–400.
pubmed: 32170326
pmcid: 7311646
doi: 10.1093/ijnp/pyaa018
Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.
pubmed: 31572236
pmcid: 6751381
doi: 10.3389/fpsyt.2019.00650
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025–33.
pubmed: 33972795
pmcid: 8205851
doi: 10.1038/s41591-021-01336-3
Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513–21.
pubmed: 10731626
doi: 10.1016/S0893-133X(99)00148-7
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486–97.
pubmed: 29728331
doi: 10.1016/S2215-0366(18)30135-4
Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;84:221–8.
doi: 10.1016/j.pnpbp.2018.03.003
Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015;5:e634.
pubmed: 26371762
pmcid: 5068803
doi: 10.1038/tp.2015.138
Curry DW, Young MB, Tran AN, Daoud GE, Howell LL. Separating the agony from ecstasy: R(−)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology. 2018;128:196–206.
pubmed: 28993129
doi: 10.1016/j.neuropharm.2017.10.003
Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM, et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology. 2017;234:2883–95.
pubmed: 28741031
pmcid: 5693755
doi: 10.1007/s00213-017-4684-8
Hake HS, Davis JKP, Wood RR, Tanner MK, Loetz EC, Sanchez A, et al. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav. 2019;199:343–50.
pubmed: 30529341
doi: 10.1016/j.physbeh.2018.12.007
Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462–71.
pubmed: 31733631
doi: 10.1038/s41386-019-0569-3
Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.
pubmed: 16515684
pmcid: 1448202
doi: 10.1186/1471-2210-6-6
Verrico CD, Lynch L, Fahey MA, Fryer A-K, Miller GM, Madras BK. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol. 2008;22:187–202.
pubmed: 18308800
doi: 10.1177/0269881107083639
Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch K-P, Robledo P, et al. 3,4-Methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry. 2007;62:669–79.
pubmed: 17306775
doi: 10.1016/j.biopsych.2006.11.005
Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, et al. Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and/or serotonin transporters. Curr Neuropharmacol. 2011;9:91–5.
pubmed: 21886569
pmcid: 3137209
doi: 10.2174/157015911795017254
Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172:3412–25.
pubmed: 25765500
pmcid: 4500375
doi: 10.1111/bph.13128
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay J-M, et al. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 2008;28:2933–40.
pubmed: 18337424
pmcid: 6670669
doi: 10.1523/JNEUROSCI.5723-07.2008
van Wel JHP, Kuypers KPC, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One. 2012;7:e40187.
pubmed: 22808116
pmcid: 3393729
doi: 10.1371/journal.pone.0040187
Kuypers KPC, de la Torre R, Farre M, Pizarro N, Xicota L, Ramaekers JG. MDMA-induced indifference to negative sounds is mediated by the 5-HT 2A receptor. Psychopharmacology. 2018;235:481–90.
pubmed: 28735368
doi: 10.1007/s00213-017-4699-1
Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481–91.
pubmed: 23727882
doi: 10.1007/s00221-013-3579-0
Zhang G, Ásgeirsdóttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW. Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. Neuropharmacology. 2013;64:403–13.
pubmed: 22722027
doi: 10.1016/j.neuropharm.2012.06.007
Cameron L, Benson CJ, Dunlap LE, Olson DE. Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci. 2018;9:1582–90.
pubmed: 29664276
doi: 10.1021/acschemneuro.8b00134
Cameron L, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261–70.
pubmed: 30829033
doi: 10.1021/acschemneuro.8b00692
Winstanley CA, Chudasama Y, Dalley JW, Theobald DEH, Glennon JC, Robbins TW. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology. 2003;167:304–14.
pubmed: 12677356
doi: 10.1007/s00213-003-1398-x
Darmani NA, Shaddy J, Gerdes CF. Differential ontogenesis of three DOI-induced behaviors in mice. Physiol Behav. 1996;60:1495–1500.
pubmed: 8946497
doi: 10.1016/S0031-9384(96)00323-X
Pierre A, Van Schuerbeek A, Allaoui W, Van Laere S, Singewald N, Van Eeckhaut A, et al. Effects of ghrelin receptor activation on forebrain dopamine release, conditioned fear and fear extinction in C57BL/6J mice. J Neurochem. 8;154:389–403.
Paxinos G, Franklin KB. Paxinos and Franklin’s the mouse brain in stereotaxic coordinates. Academic Press; 2019.
De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, et al. Loss of system xc− does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci. 2011;31:5792–803.
pubmed: 21490221
pmcid: 6622811
doi: 10.1523/JNEUROSCI.5465-10.2011
Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, Tóth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin1A receptors. Proc Natl Acad Sci USA. 2000;97:14731–6.
pubmed: 11121072
pmcid: 18987
doi: 10.1073/pnas.97.26.14731
Zussy C, Gómez-Santacana X, Rovira X, De Bundel D, Ferrazzo S, Bosch D, et al. Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4. Mol Psychiatry. 2018;23:509–20.
pubmed: 27994221
doi: 10.1038/mp.2016.223
Albertini G, Walrave L, Demuyser T, Massie A, De, Bundel D, et al. 6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain. Epilepsia. 2018;59:67–78.
pubmed: 29152735
doi: 10.1111/epi.13943
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
pubmed: 22743772
doi: 10.1038/nmeth.2019
Wheeler A, Henriques R. Standard and super-resolution bioimaging data analysis: a primer. 312. Wiley Online Library; 2017.
Maxwell SE, Delaney HD, Kelley K. Designing experiments and analyzing data: a model comparison perspective. Routledge; 2017.
Canal CE, da Silva UBO, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology. 2010;209:163–74.
pubmed: 20165943
pmcid: 2868321
doi: 10.1007/s00213-010-1784-0
De Bundel D, Gangarossa G, Biever A, Bonnefont X, Valjent E. Cognitive dysfunction, elevated anxiety, and reduced cocaine response in circadian clock-deficient cryptochrome knockout mice. Front Behav Neurosci. 2013;7:152.
pubmed: 24187535
pmcid: 3807562
doi: 10.3389/fnbeh.2013.00152
Puighermanal E, Castell L, Esteve-Codina A, Melser S, Kaganovsky K, Zussy C, et al. Functional and molecular heterogeneity of D2R neurons along dorsal-ventral axis in the striatum. Nat Commun. 2020;11:1957.
pubmed: 32327644
pmcid: 7181842
doi: 10.1038/s41467-020-15716-9
Bullitt E. Expression of C-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. J Comp Neurol. 1990;296:517–30.
pubmed: 2113539
doi: 10.1002/cne.902960402
Marek R, Sun Y, Sah P. Neural circuits for a top-down control of fear and extinction. Psychopharmacology. 2019;236:313–20.
pubmed: 30215217
doi: 10.1007/s00213-018-5033-2
Bocchio M, Fucsina G, Oikonomidis L, McHugh SB, Bannerman DM, Sharp T, et al. Increased serotonin transporter expression reduces fear and recruitment of parvalbumin interneurons of the amygdala. Neuropsychopharmacology. 2015;40:3015–26.
pubmed: 26052039
pmcid: 4864439
doi: 10.1038/npp.2015.157
Jiang X, Xing G, Yang C, Verma A, Zhang L, Li H. Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology. 2009;34:410–23.
pubmed: 18536707
doi: 10.1038/npp.2008.71
Ruotsalainen S, MacDonald E, Koivisto E, Stefanski R, Haapalinna A, Riekkinen P, et al. 5 -HT1A Receptor agonist (8-OH-DPAT) and 5-HT2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task. J Psychopharmacol. 1998;12:177–85.
pubmed: 9694031
doi: 10.1177/026988119801200210
Hjorth S, Magnusson T. The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn-Schmiedebergs Arch Pharmacol. 1988;338:463–71.
pubmed: 2469021
doi: 10.1007/BF00179315
Odland AU, Jessen L, Kristensen JL, Fitzpatrick CM, Andreasen JT. The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation. Neuropharmacology. 2021;183:107838.
pubmed: 31693871
doi: 10.1016/j.neuropharm.2019.107838
Papakosta V-M, Kalogerakou S, Kontis D, Anyfandi E, Theochari E, Boulougouris V, et al. 5-HT2C receptor involvement in the control of persistence in the Reinforced Spatial Alternation animal model of obsessive–compulsive disorder. Behav Brain Res. 2013;243:176–83.
pubmed: 23327741
doi: 10.1016/j.bbr.2013.01.005
Hameleers R, Blokland A, Steinbusch HWM, Visser-Vandewalle V, Temel Y. Hypomobility after DOI administration can be reversed by subthalamic nucleus deep brain stimulation. Behav Brain Res. 2007;185:65–7.
pubmed: 17727968
doi: 10.1016/j.bbr.2007.07.011
Krebs-Thomson K, Geyer MA. Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology. 1998;140:69–74.
pubmed: 9862404
doi: 10.1007/s002130050740
Wing LL, Tapson GS, Geyer MA. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology. 1990;100:417–25.
pubmed: 2138338
doi: 10.1007/BF02244617
Mittman SM, Geyer MA. Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology. 1991;105:69–76.
pubmed: 1745714
doi: 10.1007/BF02316866
Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, et al. 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009;34:1958–67.
pubmed: 19322172
doi: 10.1038/npp.2009.29
Onaivi ES, Bishop-Robinson C, Darmani NA, Sanders-Bush E. Behavioral effects of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test. Life Sci. 1995;57:2455–66.
pubmed: 8847967
doi: 10.1016/0024-3205(95)02242-9
Nic Dhonnchadha BÁ, Hascoët M, Jolliet P, Bourin M. Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res. 2003;147:175–84.
pubmed: 14659583
doi: 10.1016/S0166-4328(03)00179-7
Ripoll N, Hascoët M, Bourin M. Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res. 2006;166:131–9.
pubmed: 16154212
doi: 10.1016/j.bbr.2005.07.013
Lapin IP. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharm Biochem Behav. 1993;44:241–3.
doi: 10.1016/0091-3057(93)90305-D
Lin HQ, Burden PM, Christie MJ, Johnston GA. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharm Biochem Behav. 1999;62:403–8.
doi: 10.1016/S0091-3057(98)00191-9
Biala G, Kruk M. Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. J Pharm Pharmacol. 2009;61:493–502.
pubmed: 19298697
doi: 10.1211/jpp.61.04.0012
LeDoux J. The amygdala. Curr Biol. 2007;17:R868–74.
pubmed: 17956742
doi: 10.1016/j.cub.2007.08.005
Maćkowiak M, Chocyk A, Fijał K, Czyrak A, Wedzony K. c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Brain Res Mol Brain Res. 1999;71:358–63.
pubmed: 10521592
doi: 10.1016/S0169-328X(99)00195-3
Martin DA, Nichols CD. Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine. 2016;11:262–77.
pubmed: 27649637
pmcid: 5050000
doi: 10.1016/j.ebiom.2016.08.049
de Paula Soares V, Zangrossi H. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats. Behav Brain. 2009;197:178–85.
doi: 10.1016/j.bbr.2008.08.027
Petit-Demoulière B, Massé F, Cogrel N, Hascoët M, Bourin M. Brain structures implicated in the four-plate test in naïve and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. Behav Brain Res. 2009;204:200–5.
pubmed: 19523493
doi: 10.1016/j.bbr.2009.06.006
Hessel M, Pape H-C, Seidenbecher T. Stimulation of 5-HT receptors in anterodorsal BNST guides fear to predictable and unpredictable threat. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;39:56–69.
doi: 10.1016/j.euroneuro.2020.08.006
Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2014;29:57–68.
pubmed: 25389218
doi: 10.1177/0269881114555249
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020;284:112749.
pubmed: 31931272
doi: 10.1016/j.psychres.2020.112749
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.
pubmed: 27909164
pmcid: 5367551
doi: 10.1177/0269881116675512
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.
pubmed: 27909165
pmcid: 5367557
doi: 10.1177/0269881116675513
Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:11–24.
pubmed: 31382100
doi: 10.1016/j.jad.2019.07.076
Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin. 2016;11:53–60.
pubmed: 26909323
doi: 10.1016/j.nicl.2015.08.009
Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638–46.
pubmed: 27249781
pmcid: 5026740
doi: 10.1038/npp.2016.82
Risbrough VB, Brodkin JD, Geyer MA. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology. 2003;28:654–63.
pubmed: 12655310
doi: 10.1038/sj.npp.1300079
Zhao Y, Bijlsma EY, ter Heegde F, Verdouw MP, Garssen J, Newman-Tancredi A, et al. Activation of somatodendritic 5-HT 1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test. Psychopharmacology. 2019;236:1171–85.
pubmed: 30539269
doi: 10.1007/s00213-018-5124-0
Wang C-C, Lin H-C, Chan Y-H, Gean P-W, Yang YK, Chen PS. 5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. Int J Neuropsychopharmacol. 2013;16:2027–39.
pubmed: 23823694
doi: 10.1017/S1461145713000473
Koseki H, Matsumoto M, Togashi H, Miura Y, Fukushima K, Yoshioka M. Alteration of synaptic transmission in the hippocampal-mPFC pathway during extinction trials of context-dependent fear memory in juvenile rat stress models. Synapse. 2009;63:805–13.
pubmed: 19504621
doi: 10.1002/syn.20657
de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.
pubmed: 34686347
doi: 10.1016/j.celrep.2021.109836
Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology. 1996;124:107–16.
pubmed: 8935805
doi: 10.1007/BF02245610
Orejarena MJ, Lanfumey L, Maldonado R, Robledo P. Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour. Int J Neuropsychopharmacol. 2011;14:927–40.
pubmed: 20942998
doi: 10.1017/S1461145710001215
Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology. 1996;15:116–24.
pubmed: 8840347
doi: 10.1016/0893-133X(95)00160-F
Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA. Role of the serotonin 5-HT 2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology. 2005;178:505–13.
pubmed: 15765263
doi: 10.1007/s00213-004-2030-4
Pitts EG, Minerva AR, Chandler EB, Kohn JN, Logun MT, Sulima A, et al. 3,4-Methylenedioxymethamphetamine increases affiliative behaviors in squirrel monkeys in a serotonin 2A receptor-dependent manner. Neuropsychopharmacology. 2017;42:1962–71.
pubmed: 28425496
pmcid: 5561347
doi: 10.1038/npp.2017.80